-
Another innovative drug against advanced solid tumor has entered the clinic!
Time of Update: 2016-10-18
This week (2016.10.8-10.16), only one drug is in the review status, i.e Beida Pharmaceutical imported and declared its innovative drug x-396 capsule, acceptance No jxhl160000114 This product was revie
-
Life and death of generic drugs: drugs failing to complete conformity assessment within the period will be cancelled
Time of Update: 2016-10-18
The R & D investment of Chinese pharmaceutical manufacturers is insufficient, the innovation ability is not strong, and the quality of some generic drugs is far behind the international advanced level
-
Hualing medicine announces the first global satisfactory result of phase II clinical trial of single drug treatment of new diabetes medicine
Time of Update: 2016-10-17
October 17, 2016, Shanghai, China, San Francisco, California, USA Hualing pharmaceutical, a leading innovative pharmaceutical R & D enterprise, today announced that the phase II clinical trial of "new
-
For the first time, China will become the first country to research and develop 1.1 new drugs in the world!
Time of Update: 2016-10-15
Recently, "2016 Beijing international medical engineering transformation Summit Forum" was held in Zhongguancun medical engineering transformation center in Beijing to promote collaborative innovation
-
Innovation and breakthrough of Fosun medicine and bio medicine: the clinical application of Fosun Hanlin bio modified monoclonal antibody has been approved in three places on both sides of the Taiwan Strait
Time of Update: 2016-10-14
On October 14, 2016, the latest A-share announcement issued by Fosun Pharmaceutical showed that its holding subsidiary Shanghai Fuhong Hanlin Biotechnology Co., Ltd (hereinafter referred to as "Fuhong
-
The first new drug "pegabin" of Tebo biology was approved for marketing
Time of Update: 2016-10-05
According to the Fujian food and drug administration, the new biological product "pegabin" (pegylated interferon 2B injection) developed by Xiamen Tebao biological Co., Ltd has recently been officiall
-
Drug review center held drug review consultation meeting in September 2016
Time of Update: 2016-09-30
From September 20 to 23, 2016, the drug review center organized the 8th drug review consultation meeting in 2016 in Jiangxi Hotel, Beijing 189 experts were invited to attend the meeting At the same ti
-
Chronic obstructive pulmonary disease (COPD), the "chronic killer" of respiratory system
Time of Update: 2016-09-29
The 2016 annual meeting of the European Respiratory Society (ERS 2016) was held in London, UK from September 3 to 7 As the "first show" of China day, academician Zhong Nanshan released an important re
-
Clinical effectiveness evaluation is a necessary supplementary course for generic pharmaceutical enterprises
Time of Update: 2016-09-27
[news] recently, CFDA organized the drafting of "general considerations for clinical effectiveness test of conformity evaluation of quality and efficacy of generic drugs (Draft for comments)", and ask
-
Microchip biology: independent research and development of new anticancer drugs, creating many firsts
Time of Update: 2016-09-21
Recently, Lu Xianping, who used to fly all over the world, is even busier Just half an hour before Nanfang Daily's visit, he just finished filming a documentary about innovation on Mango and Korean TV
-
Top 5 net profit of listed pharmaceutical enterprises in the first half of 2016
Time of Update: 2016-09-19
Recently, the semi annual report of 2016 of listed companies has been published successively, with the net profit of 5 pharmaceutical companies exceeding 1 billion yuan, with a year-on-year growth of
-
Clinical approval documents and related technologies for saisheng pharmaceutical to purchase new peptide drugs of category 1.1
Time of Update: 2016-09-18
Saisheng pharmaceutical announced on September 18, 2016 that recently, the company signed the technology transfer contract with Peking University Cancer Hospital and Beijing Institute of cancer preven
-
The most stringent generic drug evaluation system in the world -- requirements of Japan Drug Administration (Ⅰ)
Time of Update: 2016-09-18
This paper is compiled by Mr Xie Mufeng of Shanghai food and Drug Inspection Institute Due to its long length, it will be pushed continuously for three days This is the first part The article "becaus
-
26 billion yuan in the lung cancer market: targeted drugs are competing, with an average annual growth of 122% for icotinib
Time of Update: 2016-09-17
In May this year, the first batch of national drug price negotiation results were released, and the price negotiation procedures for non-small cell lung cancer targeted drugs exetane (Zhejiang Beida K
-
Publication of preclinical research results of ivetinib, a new anti lung cancer drug
Time of Update: 2016-09-15
Hangzhou, September 14, 2016 / Meitong news agency / -- recently, the preclinical research results of ivetinib (ac0010), the first third representative skin growth factor receptor (EGFR) inhibitor in
-
Zhejiang medicine "1 billion level" new drug is expected to go on the market in October
Time of Update: 2016-09-15
It is regarded as the most effective "the latest generation of quinolones" in the same kind of drugs by the industry The research and development progress and marketing schedule of nanofloxacin malate
-
Witness the birth of IKO! Xiaohulu opens the door and waits for you!
Time of Update: 2016-09-13
Speaking of ikosin, many mothers will think of pink, green and lovely little gourd In 1994, dyne pharmaceutical was officially established, and its mission is to "make millions of Chinese children hea
-
Press | China clinical trial approval of bgb-a317
Time of Update: 2016-09-13
Beijing, September 12, 2016 - Baiji Shenzhou (NASDAQ: bgne) is a biomedical company focusing on the development of innovative molecular targeting and tumor immune drugs for cancer treatment, and its p
-
Approval for clinical trial of Baiji Shenzhou PD-1 McAb bgb-a317
Time of Update: 2016-09-12
Today (September 12), after "Baiji Shenzhou anticancer drug bgb-290 obtained the drug clinical trial approval issued by CFDA", Baiji Shenzhou announced that the PD-1 McAb bgb-a317 for the treatment o
-
FDA has approved 45 small molecule targeted drugs, only 13 of which are listed in China
Time of Update: 2016-09-07
Cancer has become the most lethal cause of human disease worldwide, and the incidence rate and mortality rate of cancer worldwide continues to rise According to the data of 85.5 million population cov
